Eugia Pharma Specialities Limited
UkraineAll drugs from this manufacturer
-
The drug is intended for the treatment of postmenopausal women with advanced breast cancer (hormone receptor-positive), as well as for the adjuvant treatment of early-stage invasive breast cancer.
Dosage form: tablets, film-coated
Active substance Dosage anastrozole 1 mg ATC: L02BG03
-
The drug is prescribed for the treatment of patients with chronic lymphocytic leukemia (CLL), as well as for the treatment of indolent B-cell non-Hodgkin lymphoma (NHL) in cases of disease progression during or 6 months after rituximab therapy.
Dosage form: powder for preparation of concentrate for infusion solution
Active substance Dosage bendamustine 25 mg ATC: L01AA09
-
The drug is intended for the treatment of patients with chronic lymphocytic leukemia (CLL), as well as for the treatment of indolent B-cell non-Hodgkin lymphoma (NHL) in cases of disease progression during or 6 months after rituximab therapy.
Dosage form: powder for preparation of concentrate for infusion solution
Active substance Dosage bendamustine 100 mg ATC: L01AA09
-
The drug is used for the treatment of multiple myeloma (both as part of combination therapy and as monotherapy) and mantle cell lymphoma.
Dosage form: powder for injection solution
Active substance Dosage bortezomib 3.5 mg ATC: L01XX32
-
The drug is intended for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are not candidates for standard induction chemotherapy.
Dosage form: powder for concentrate for infusion solution
Active substance Dosage decitabine 50 mg ATC: L01BC08
-
The drug is used for adjuvant therapy in postmenopausal women with early-stage invasive breast cancer (after 2–3 years of tamoxifen therapy), as well as for the treatment of advanced breast cancer in postmenopausal women if the disease has progressed after the use of antiestrogens.
Dosage form: tablets, film-coated
Active substance Dosage exemestane 25 mg ATC: L02BG06
-
The drug is used to treat patients with advanced colorectal cancer. It may be used either as monotherapy or in combination with other medicinal products (e.g., 5-fluorouracil, folinic acid, cetuximab, bevacizumab, or capecitabine) depending on the stage of the disease and previous treatment.
Dosage form: concentrate for infusion solution
Active substance Dosage irinotecan 20 mg/ml ATC: L01CE02
-
The drug is prescribed for the treatment of gastrointestinal stromal tumor (GIST), progressive renal cell carcinoma (RCC), adjuvant therapy for RCC, as well as progressive neuroendocrine tumors of the pancreas.
Dosage form: capsules
Active substance Dosage sunitinib 12.5 mg ATC: L01EX01
-
The drug is prescribed for the treatment of gastrointestinal stromal tumor (GIST), progressive renal cell carcinoma (RCC), adjuvant therapy for RCC, as well as progressive pancreatic neuroendocrine tumors.
Dosage form: capsules
Active substance Dosage sunitinib 50 mg ATC: L01EX01
-
The drug is used for hormone therapy in postmenopausal women with various forms of breast cancer (adjuvant therapy, treatment of advanced cancer, neoadjuvant therapy).
Dosage form: tablets, film-coated
Active substance Dosage letrozole 2.5 mg ATC: L02BG04
-
The drug is used for the treatment of malignant pleural mesothelioma, as well as non-small cell lung cancer (both in combination with cisplatin and as monotherapy in certain cases).
Dosage form: powder for concentrate for infusion solution
Active substance Dosage pemetrexed 100 mg ATC: L01BA04
-
The drug is used for the treatment of malignant pleural mesothelioma, as well as non-small cell lung cancer (both in combination with cisplatin and as monotherapy in certain cases).
Dosage form: powder for concentrate for infusion solution
Active substance Dosage pemetrexed 500 mg ATC: L01BA04